Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
European Urology Oncology
|
November 11, 2023
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office
Joost L Boormans, Richard Sylvester, Lynn Anson-Cartwright, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 10, 2025
The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial
Kara M Ruicci, Aisling Barry, Xiang Y Ye, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 24, 2026
Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes
John Mohan Mathew, Hannah Bacon, Jeff Winter, et al.
BMJ Open
|
April 25, 2020
[<sup>18</sup>F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
Rachel M Glicksman, Ur Metser, John Valliant, et al.
Technical Innovations & Patient Support in Radiation Oncology
|
March 6, 2024
Prospective evaluation of patient-reported anxiety and experiences with adaptive radiation therapy on an MR-linac
Amanda Moreira, Winnie Li, Alejandro Berlin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 28, 2022
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer
Rachel M Glicksman, Matthew Ramotar, Ur Metser, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 25, 2025
Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial
Rachel M Glicksman, Jeff Winter, Andrew McPartlin, et al.
Clinical and Translational Radiation Oncology
|
April 21, 2026
The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial
Kara M Ruicci, Joelle Helou, Aisling Barry, et al.
European Urology
|
March 9, 2021
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis
Rachel M Glicksman, Ur Metser, Douglass Vines, et al.
JAMA Oncology
|
January 3, 2020
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review
Rachel M Glicksman, Michael C Tjong, Wellington F P Neves-Junior, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
European Urology Oncology
|
November 11, 2023
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office
Joost L Boormans, Richard Sylvester, Lynn Anson-Cartwright, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 10, 2025
The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial
Kara M Ruicci, Aisling Barry, Xiang Y Ye, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 24, 2026
Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes
John Mohan Mathew, Hannah Bacon, Jeff Winter, et al.
BMJ Open
|
April 25, 2020
[<sup>18</sup>F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
Rachel M Glicksman, Ur Metser, John Valliant, et al.
Technical Innovations & Patient Support in Radiation Oncology
|
March 6, 2024
Prospective evaluation of patient-reported anxiety and experiences with adaptive radiation therapy on an MR-linac
Amanda Moreira, Winnie Li, Alejandro Berlin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 28, 2022
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer
Rachel M Glicksman, Matthew Ramotar, Ur Metser, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 25, 2025
Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial
Rachel M Glicksman, Jeff Winter, Andrew McPartlin, et al.
Clinical and Translational Radiation Oncology
|
April 21, 2026
The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial
Kara M Ruicci, Joelle Helou, Aisling Barry, et al.
European Urology
|
March 9, 2021
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis
Rachel M Glicksman, Ur Metser, Douglass Vines, et al.
JAMA Oncology
|
January 3, 2020
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review
Rachel M Glicksman, Michael C Tjong, Wellington F P Neves-Junior, et al.
Page
of 6